EE04141B1 - 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga - Google Patents

5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga

Info

Publication number
EE04141B1
EE04141B1 EEP200000141A EEP200000141A EE04141B1 EE 04141 B1 EE04141 B1 EE 04141B1 EE P200000141 A EEP200000141 A EE P200000141A EE P200000141 A EEP200000141 A EE P200000141A EE 04141 B1 EE04141 B1 EE 04141B1
Authority
EE
Estonia
Prior art keywords
combination
reuptake inhibitor
partial agonist
ht1b antagonist
ht1b
Prior art date
Application number
EEP200000141A
Other languages
English (en)
Estonian (et)
Inventor
Berg Stefan
Ross Svante
Thorberg Seth-Olov
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of EE200000141A publication Critical patent/EE200000141A/xx
Publication of EE04141B1 publication Critical patent/EE04141B1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Replacement Of Web Rolls (AREA)
  • Winding, Rewinding, Material Storage Devices (AREA)
EEP200000141A 1997-09-18 1998-09-09 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga EE04141B1 (et)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9703375A SE9703375D0 (sv) 1997-09-18 1997-09-18 A new combination
PCT/SE1998/001601 WO1999013877A1 (fr) 1997-09-18 1998-09-09 Combinaison d'un inhibiteur de recaptage 5-ht et un antagoniste de h5-ht1b ou agoniste partiel

Publications (2)

Publication Number Publication Date
EE200000141A EE200000141A (et) 2001-02-15
EE04141B1 true EE04141B1 (et) 2003-10-15

Family

ID=20408295

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200000141A EE04141B1 (et) 1997-09-18 1998-09-09 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga

Country Status (29)

Country Link
US (1) US6159971A (fr)
EP (1) EP1014985B1 (fr)
JP (1) JP2001516718A (fr)
KR (1) KR20010024076A (fr)
CN (1) CN1195519C (fr)
AR (1) AR015448A1 (fr)
AT (1) ATE240733T1 (fr)
AU (1) AU752722B2 (fr)
BR (1) BR9812088A (fr)
CA (1) CA2302382A1 (fr)
DE (1) DE69814882T2 (fr)
DK (1) DK1014985T3 (fr)
EE (1) EE04141B1 (fr)
ES (1) ES2200370T3 (fr)
HU (1) HUP0200602A3 (fr)
IL (1) IL134776A0 (fr)
IS (1) IS5406A (fr)
MY (1) MY116280A (fr)
NO (1) NO20001399L (fr)
NZ (1) NZ503171A (fr)
PL (1) PL339371A1 (fr)
PT (1) PT1014985E (fr)
RU (1) RU2214824C2 (fr)
SE (1) SE9703375D0 (fr)
SK (1) SK2852000A3 (fr)
TR (1) TR200000727T2 (fr)
TW (1) TW589183B (fr)
WO (1) WO1999013877A1 (fr)
ZA (1) ZA987817B (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
UA77650C2 (en) * 1999-12-06 2007-01-15 Lundbeck & Co As H Use of serotonin reuptake inhibitor in combination with deramcyclane
WO2002066454A1 (fr) * 2001-02-21 2002-08-29 Sankyo Company, Limited Derives de chromene
CZ20033267A3 (en) * 2001-05-01 2004-06-16 H. Lundbeck A/S The use of enantiomeric pure escitalopram
DK1408976T5 (da) * 2001-07-20 2011-01-10 Psychogenics Inc Behandling af ADHD (Attention deficit hyperactivity disorder)
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
SE0203778D0 (sv) * 2002-12-09 2002-12-09 Astrazeneca Ab A new oral immediated release dosage form
AR047553A1 (es) 2003-07-04 2006-01-25 Lundbeck & Co As H La combinacion de un inhibidor de reabsorcion de serotonina y agomelatina
KR100511288B1 (ko) * 2003-11-14 2005-08-31 엘지전자 주식회사 4대의 압축기를 구비한 공기조화기의 실외기
WO2006091725A1 (fr) * 2005-02-23 2006-08-31 The Silvan S. Tomkins Institute Traitement de l'anhedonie
US8227476B2 (en) 2005-08-03 2012-07-24 Sprout Pharmaceuticals, Inc. Use of flibanserin in the treatment of obesity
FR2890862B1 (fr) * 2005-09-19 2008-01-25 Sanofi Aventis Sa Association d'agoniste aux recepteurs beta 3 et d'inhibiteur de la recapture de monoamnies, compostion pharmaceutique la contenant et son utilisation en therapeutique.
CA2626134C (fr) 2005-10-29 2013-12-24 Boehringer Ingelheim International Gmbh Derives de benzimidazolone utiles pour le traitement des troubles premenstruels et d'autres troubles sexuels chez la femme
US7893053B2 (en) 2006-06-16 2011-02-22 Theracos, Inc. Treating psychological conditions using muscarinic receptor M1 antagonists
RU2455981C2 (ru) * 2006-06-16 2012-07-20 Теракос, Инк. Лечение ожирения антагонистами мускаринового рецептора м1
US8748419B2 (en) 2006-06-16 2014-06-10 Theracos, Inc. Treating obesity with muscarinic receptor M1 antagonists
US20090312242A1 (en) 2006-06-30 2009-12-17 Ramiro Castro Flibanserin for the treatment of urinary incontinence and related diseases
CL2007002214A1 (es) 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
CA2660476C (fr) 2006-08-14 2015-11-17 Boehringer Ingelheim International Gmbh Formulations de flibanserine et leur procede de fabrication
EP2056797A2 (fr) 2006-08-25 2009-05-13 Boehringer Ingelheim International GmbH Système de libération contrôlée et procédé de préparation correspondant
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2162792T3 (es) * 1991-09-18 2002-01-16 Glaxo Group Ltd Derivados de benzanilida como antagonistas de 5-ht1d.
GB9119932D0 (en) * 1991-09-18 1991-10-30 Glaxo Group Ltd Chemical compounds
SE9601110D0 (sv) * 1996-03-22 1996-03-22 Astra Ab Substituted 1,2,3,4-tetrahydronaphthalene derivatives
SE9703374D0 (sv) * 1997-09-18 1997-09-18 Astra Ab A new combination

Also Published As

Publication number Publication date
HUP0200602A2 (hu) 2002-07-29
AU9193098A (en) 1999-04-05
WO1999013877A1 (fr) 1999-03-25
DE69814882D1 (de) 2003-06-26
TW589183B (en) 2004-06-01
EP1014985A1 (fr) 2000-07-05
BR9812088A (pt) 2000-09-26
JP2001516718A (ja) 2001-10-02
ZA987817B (en) 1999-03-18
IS5406A (is) 2000-03-15
CN1278729A (zh) 2001-01-03
KR20010024076A (ko) 2001-03-26
CA2302382A1 (fr) 1999-03-25
RU2214824C2 (ru) 2003-10-27
CN1195519C (zh) 2005-04-06
TR200000727T2 (tr) 2000-09-21
EP1014985B1 (fr) 2003-05-21
PL339371A1 (en) 2000-12-18
SK2852000A3 (en) 2000-09-12
HK1032739A1 (en) 2001-08-03
EE200000141A (et) 2001-02-15
US6159971A (en) 2000-12-12
NO20001399L (no) 2000-05-10
PT1014985E (pt) 2003-10-31
NZ503171A (en) 2002-02-01
AR015448A1 (es) 2001-05-02
IL134776A0 (en) 2001-04-30
ATE240733T1 (de) 2003-06-15
DK1014985T3 (da) 2003-09-15
HUP0200602A3 (en) 2003-04-28
NO20001399D0 (no) 2000-03-17
DE69814882T2 (de) 2004-05-19
ES2200370T3 (es) 2004-03-01
AU752722B2 (en) 2002-09-26
SE9703375D0 (sv) 1997-09-18
MY116280A (en) 2003-12-31

Similar Documents

Publication Publication Date Title
EE04141B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon h5-HT1B antagonisti või osalise agonistiga
HUP0203586A3 (en) The combination of a serotonin reuptake inhibitor and a 5-ht2c antagonist, inverse agonist or partial agonist
DK0736525T3 (da) Benzonitriler som 5-HT-agonister og -antagonister
FI981132L (fi) Palvelun luvattoman käytön estäminen
DK2253620T3 (da) Substituerede 3-cyanoquinoliner som protein-tyrosinkinase-inhibitorer
NO20032797L (no) Substituerte pyridoindoler som serotonin agonister og antagonister
NO993848D0 (no) Fremgangsmåte for bestemmelse av oljeegenskaper
DE60003148D1 (de) Bestimmung der Cachezeit
EP1289526A4 (fr) Agonistes du recepteur de la melanocortine
NO20002121D0 (no) Benzotiazol-protein-tyrosin-kinaseinhibitorer
PT1131291E (pt) Antagonistas iii do receptor 4-aroil-piperidin-ccr-3
ID27574A (id) Inhibitor enzim
DK1027332T3 (da) Hidtil ukendte lactametalloproteaseinhibitorer
EE200000146A (et) Monoamiini oksüdaasi inhibiitori kombinatsioon h5-HT 1B antagonisti või osalise agonistiga
EE03553B1 (et) 5-HT tagasihaarde inhibiitori kombinatsioon selektiivse 5-HT1A antagonistiga
EE200100014A (et) Antidepressiivse toimega vahend
NO20005826L (no) Bionedbrytbare korrosjonsinhibitorer
NO994106D0 (no) Oksazolidiner som 5-HT2A-antagonister
ATE252547T1 (de) Matrixmetalloproteinaseinhibitoren
EP1023068A4 (fr) ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
DK1146874T3 (da) Vitronectinreceptoragonist
DE69903319D1 (de) Fkbp inhibitoren
EP1014973A4 (fr) ANTAGONISTES DES ADRENORECEPTEURS ALPHA 1a
EE200000143A (et) Selektiivse 5-HT 1A antagonisti kombinatsioon selektiivse h5-HT 1B antagonisti või osalise agonistiga
NO20006041D0 (no) N-Benzodioksanylmetyl-1-piperidyl-metylamin-forbindelser med affinitet for 5-HT-reseptorer

Legal Events

Date Code Title Description
KB4A Valid patent at the end of a year

Effective date: 20031231

KB4A Valid patent at the end of a year

Effective date: 20041231

KB4A Valid patent at the end of a year

Effective date: 20051231

MM4A Lapsed by not paying the annual fees

Effective date: 20050909